• BioLineRx Ltd., of Jerusalem, said it is raising about $15 million through agreements with U.S. institutional investors to place about 5.2 million American depositary shares (ADSs) priced at $2.86 each, along with warrants to purchase up to 2.6 million additional ADSs at an exercise price of $3.57. Net proceeds are expected to total about $14.1 million and will be used for working capital and for continued development of the firm's 18 compounds.
Read More
Protalix Biotherapeutics Inc., of Carmiel, Israel, priced a public offering of 4.5 million shares at $5.25 per share, a 14.3 percent discount to Wednesday's closing price, which will bring in about $23.6 million in gross proceeds.
Read More
VANCOUVER, British Columbia – The recent history of biology has been dominated by the Human Genome Project, but even as the first complete sequence was published 11 years ago, it was evident that translating that into something of use for human health and medicine would require a far greater undertaking – of mapping and understanding all the proteins in the human body.
Read More
LONDON – UK start-up Oxford Nanopore Ltd. is poised to challenge the dominance of the two world-leading U.S. DNA sequencer manufacturers with the imminent launch of a miniature sequencing machine that is the size of a USB memory stick and is expected to retail for less than $900.
Read More
A new era in life sciences research in Norway is beginning this year. Two new programs, the Program on Human Biobanks and Health Data (BIOBANK) and a program called Biotechnology for Innovation (BIOTEK2021), are issuing their first call for proposals, with a total of NOK215 million (US$37.8 million) on offer initially.
Read More
LONDON – A type of drug that is already being evaluated as a treatment for Huntington's disease could have a valuable side effect that would also help reduce the progress of the condition, a new study suggested.
Read More
VANCOUVER, British Columbia – While all tumors have the same pathogenic root of one cell deciding to act differently and grow in an unregulated way, that's where their similarities end, as cancer genomics is now revealing.
Read More
